News

The increase of approximately $796,000 in revenues from the fourth quarter of 2009 compared to the fourth quarter of 2010 was primarily due to increased licensing fees due

The company has received the US Food and Drug Administration approval for Axiron on 23 November 2010. Eli Lilly said the study results demonstrated that Axiron helped in

PGXL Laboratories provides pharmacogenetic testing and interpretive services. It has developed CYP2C9/VKORC1 tests for accurate anticoagulant dosing. Along with its clinical practice, PGXL performs contract research for manufacturers

The Phase 3 trials include two studies in treatment-naive and one study in treatment-experienced chronic genotype-1 HCV patients. Boehringer Ingelheim expects to conduct the two Phase 3 studies

The biodegradable nanoparticles could be topically applied to the skin or injected into the body to treat MRSA skin infections. IBM Research – Almaden Advanced Organic Materials scientist

REG1 is a two-component system consisting of pegnivacogin, a highly selective Factor IXa (FIXa) inhibitor and anivamersen, its complementary specific active control agent. The study results showed that

As per the agreement, Genzyme expects to provide access to a novel and proprietary tumor-targeting antibody, and Algeta will provide access to its Thorium platform to attach the

The new cancer treatment also attracts tumours directly. Tracy Robson and her research team at Queen’s, in collaboration with researchers at Almac Discovery, developed a new drug to

The research agreement, which was previously signed in March 2003, has been extended for another year. Accordingly, the term of the agreement will end in March 2012. As